Study 79 of 80HGH (Somatropin) literatureLancet (London, England)Top journal2026
Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.
Not reported in abstract.
Where it sits
this study against the rest of the hgh (somatropin) corpus4
Preclinical
54
Observational
1
Open-label · this one
14
Randomised
7
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the HGH (Somatropin) corpus
AEfficacy and Safety of Lonapegsomatropin in Children With Turner Syndrome: 52-Week Results From the New InsiGHTS Trial.The Journal of clinical endocrinology and metabolism · 2026 · At week 52, AHV was 9.05 cm/year for pooled lonapegsomatropin cohorts and 9.04 cm/year for the somatropin cohort.HumanBThe changes in health-related quality of life and psychological outcomes in Chinese children with short stature after growth hormone therapy.Acta psychologica · 2026 · n=162 · At 1 year, the rhGH group had higher overall and domain-specific HRQoL scores than controls (all P < 0.05).HumanBAn assessment of the global usability of quality-of-life questionnaires in children receiving recombinant growth hormone therapy.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2026 · 24 (65%) had a reported completion time less than 15 min.reviewBBenchmarking of growth hormone therapy in Hong Kong: ten-year data from the multi-centre GROWTH study.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2026 · n=351 · Median one-year change in HtSDS was 0.41 (range, -0.98, 3.4).HumanBSomatrogon versus somatropin in children with growth hormone deficiency: a real-world matched-cohort study.Annals of pediatric endocrinology & metabolism · 2023 · n=30 · AHV was similar in both groups (8.96±1.67 vs 8.84±1.57 cm/year; p=0.841)HumanAUp to 5 years of weekly somatrogon in children with growth hormone deficiency: final data from the global phase 3 study.Journal of the Endocrine Society · 2023 · n=212 · Mean annualized height velocity at OLE Year 1 was 8.11 cm/year.Human